Figulla, Hans Reiner

[["dc.bibliographiccitation.firstpage","239"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Metabolic Brain Disease"],["dc.bibliographiccitation.lastpage","251"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Nolte, Wilhelm"],["dc.contributor.author","Otto, Markus"],["dc.contributor.author","Wildberg, Jens"],["dc.contributor.author","Bahn, Erik"],["dc.contributor.author","Figulla, Hans Reiner"],["dc.contributor.author","Pralle, Lars"],["dc.contributor.author","Hartmann, Heinz"],["dc.contributor.author","Rüther, Eckhard"],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2017-09-07T11:44:42Z"],["dc.date.available","2017-09-07T11:44:42Z"],["dc.date.issued","1999"],["dc.description.abstract","Portal-systemic encephalopathy is the prototype among the neuropsychiatric disorders that fall under the term Hepatic Encephalopathies. Ammonia toxicity is central to the pathophysiology of Portal-systemic encephalopathy, and neuronal ammonia toxicity is modulated by activated astrocytes. The calcium-binding astroglial key protein S100β is released in response to glial activation, and its measurement in serum only recently became possible. Serum S100β was determined by an ultrasensitive ELISA in patients (n=36) with liver cirrhosis and transjugular intrahepatic portosystemic stent-shunt. Subclinical portal-systemic encephalopathy and overt portal-systemic encephalopathy were determined by age-adjusted psychometric tests and clinical staging, respectively. Serum S100β was specifically elevated in the presence of subclinical or early portal-systemic encephalopathy, but not arterial ammonia. S100β levels elevated above a reference value (S100β ≤ 110pg/ml) or the cut off value determined in our group of patients (112pg/ml) predicted subclinical portal-systemic encephalopathy with a specificity and sensitivity of 100 and 56.5%, respectively. Serum S100β was significantly dependent on liver dysfunction (Child-Pugh score), but was more closely related to cognitive impairments than the score. Serum S100β seems to be a promising biochemical surrogate marker for mild cognitive impairments due to portal-systemic encephalopathy."],["dc.identifier.doi","10.1023/a:1020785009005"],["dc.identifier.gro","3151726"],["dc.identifier.pmid","10850551"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8547"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","chake"],["dc.relation.issn","0885-7490"],["dc.title","Elevated Serum Levels of Astroglial S100β in Patients with Liver Cirrhosis Indicate Early and Subclinical Portal-Systemic Encephalopathy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Heart Journal"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Ferrari, M."],["dc.contributor.author","Hellige, Gerhard"],["dc.contributor.author","Schlosser, M."],["dc.contributor.author","Lang, K."],["dc.contributor.author","Frerichs, Inez"],["dc.contributor.author","Mueller, E."],["dc.contributor.author","Eisold, G."],["dc.contributor.author","Figulla, H. R."],["dc.date.accessioned","2018-11-07T10:12:56Z"],["dc.date.available","2018-11-07T10:12:56Z"],["dc.date.issued","2002"],["dc.format.extent","156"],["dc.identifier.isi","000179753300583"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40331"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","W B Saunders Co Ltd"],["dc.publisher.place","London"],["dc.relation.conference","Congress of the European-Society-of-Cardiology"],["dc.relation.eventlocation","BERLIN, GERMANY"],["dc.relation.issn","0195-668X"],["dc.title","Percutaneous aortic valve replacement with a self-expanding stent - First animal results"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1343"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Circulation"],["dc.bibliographiccitation.lastpage","1349"],["dc.bibliographiccitation.volume","104"],["dc.contributor.author","Mudra, Harald"],["dc.contributor.author","di Mario, C."],["dc.contributor.author","de Jaegere, P."],["dc.contributor.author","Figulla, H. R."],["dc.contributor.author","Macaya, C."],["dc.contributor.author","Zahn, Ralph"],["dc.contributor.author","Wennerblom, B."],["dc.contributor.author","Rutsch, W."],["dc.contributor.author","Voudris, V."],["dc.contributor.author","Regar, E."],["dc.contributor.author","Henneke, K. H."],["dc.contributor.author","Schachinger, V."],["dc.contributor.author","Zeiher, A."],["dc.date.accessioned","2018-11-07T08:38:43Z"],["dc.date.available","2018-11-07T08:38:43Z"],["dc.date.issued","2001"],["dc.description.abstract","Background-Observational studies in selected patients have shown remarkably low restenosis rates after ultrasound-guided stent implantation. However, it is unknown whether this implantation strategy improves long-term angiographic and clinical outcome in routine clinical practice. Methods and Results-A total of 550 patients with a symptomatic coronary lesion or silent ischemia were randomly assigned to either ultrasound-guided or angiography-guided implantation of less than or equal to2 tubular stents. The primary end points were angiographic dichotomous restenosis rate, minimal lumen diameter, and percent diameter stenosis after 6 months as determined by quantitative coronary angiography. Secondary end points were the occurrence rates of major adverse cardiac events (death, myocardial infarction, coronary bypass surgery, and repeat percutaneous intervention) after 6 and 12 months of follow-up. At 6 months, repeat angiography revealed no significant differences between the groups with ultrasound- or angiography-guided stent implantation with respect to dichotomous restenosis rate (24.5% versus 22.8%, P=0.68), minimal lumen diameter (1.95 +/-0.72 mm versus 1.91 +/-0.68 mm, P=0.52), and percent diameter stenosis (34.8 +/- 20.6% versus 36.8 +/- 19.6%, P=0.29), respectively. At 12 months, neither major adverse cardiac events (relative risk, 1.07; 95% CI 0.75 to 1.52; P=0.71) nor repeat percutaneous interventions (relative risk 1.04; 95% CI 0.64 to 1.67; P=0.87) were reduced in the ultrasound-guided group. Conclusions-This study does not support the routine use of ultrasound guidance for coronary stenting. Angiography-guided optimization of tubular stents can be performed with comparable angiographic and clinical long-term results."],["dc.identifier.doi","10.1161/hc3701.096064"],["dc.identifier.isi","000171131200006"],["dc.identifier.pmid","11560848"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18826"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0009-7322"],["dc.title","Randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS study)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Heart Journal"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Ferrari, M."],["dc.contributor.author","Hellige, Gerhard"],["dc.contributor.author","Schlosser, M."],["dc.contributor.author","Frerichs, Inez"],["dc.contributor.author","Damm, C."],["dc.contributor.author","Mueller, E."],["dc.contributor.author","Guyenot, V."],["dc.contributor.author","Figulla, H. R."],["dc.date.accessioned","2018-11-07T10:37:12Z"],["dc.date.available","2018-11-07T10:37:12Z"],["dc.date.issued","2003"],["dc.identifier.doi","10.1016/S0195-668X(03)94210-2"],["dc.identifier.isi","000185638800559"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45508"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","W B Saunders Co Ltd"],["dc.publisher.place","London"],["dc.relation.conference","Congress of the European-Society-of-Cardiology"],["dc.relation.eventlocation","VIENNA, AUSTRIA"],["dc.relation.eventstart","2003"],["dc.title","Percutaneous aortic valve replacement with a self-expandable stent-valve-device in the beating heart in vivo stress testing in an animal model"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","17"],["dc.bibliographiccitation.journal","Circulation"],["dc.bibliographiccitation.volume","104"],["dc.contributor.author","Reinhardt, D."],["dc.contributor.author","Guido, H."],["dc.contributor.author","Berndt, Andre"],["dc.contributor.author","Klaus-Juergen, S."],["dc.contributor.author","Sigusch, H. H."],["dc.contributor.author","Kuehnert, H."],["dc.contributor.author","Kosmehl, H."],["dc.contributor.author","Figulla, H. R."],["dc.date.accessioned","2018-11-07T08:31:49Z"],["dc.date.available","2018-11-07T08:31:49Z"],["dc.date.issued","2001"],["dc.format.extent","167"],["dc.identifier.isi","000171895000801"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17205"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.publisher.place","Philadelphia"],["dc.relation.issn","0009-7322"],["dc.title","Matrix components Tenascin C and fibronectin in idiopathic dilated cardiomyopathy"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","60"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Liver International"],["dc.bibliographiccitation.lastpage","65"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Nolte, Wilhelm"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Pahl, Karoline"],["dc.contributor.author","Unterberg, Knut"],["dc.contributor.author","Kamrowski-Kruck, Heike"],["dc.contributor.author","Schindler, Christian G."],["dc.contributor.author","Figulla, Hans Reiner"],["dc.contributor.author","Buchwald, Arnd B."],["dc.contributor.author","Hartmann, Heinz"],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2017-09-07T11:44:24Z"],["dc.date.available","2017-09-07T11:44:24Z"],["dc.date.issued","2000"],["dc.description.abstract","Aims/Background: Endothelin-1 (ET-1) may be a mediator for portal hypertension in liver cirrhosis. The aim of the present study was to determine the concentrations of ET-1 in the systemic and splanchnic circulation before and after reduction of portal hypertension by transjugular intrahepatic portosystemic shunt implantation (TIPS). Methods: Plasma concentrations of immunoreactive ET-1 were measured in peripheral venous blood samples from 25 patients with liver cirrhosis before and at 1, 3, 9 and 15 months after TIPS. Furthermore, acute effects of TIPS on ET-1 were studied in plasma samples from the hepatic vein, the portal vein 30 minutes before and after TIPS and in the femoral artery (only after TIPS) in a subgroup of 15 patients. In addition, the portocaval pressure gradient was determined before and after TIPS. Results: Before TIPS peripheral venous plasma ET-1 concentrations (n=25; median 4.2 pg/ml; range 1.9–14.7) were significantly increased in patients with refractory ascites (n=7; median 7.8, range 3.5–14.7) compared to patients with repetitive bleeding (n=18; median 3.4; range 1.9–7.1) (p=0.003). Furthermore, peripheral ET-1 concentrations correlated with the degree of liver dysfunction according to the Child-Pugh classification (Spearman's r=0.46; p=0.02). Following TIPS, peripheral ET-1 concentrations remained unchanged during a follow-up of 15 months. Before TIPS, a positive gradient of ET-1 concentrations from portalvenous to hepatovenous and peripheral venous levels was found (p<0.03). Immediately after TIPS, arterial ET-1 concentrations reached markedly increased levels in individual patients (88, 92 and 103 pg/ml). Severe systemic reactions to these high levels were not observed. Peripheral venous, hepatovenous and portalvenous ET-1 concentrations did not correlate with portocaval pressure gradients. Conclusion: Cirrhotic patients demonstrated unchanged peripheral venous ET-1 concentrations up to 15 months after TIPS. Portal congestion was associated with increased ET-1 levels in the prehepatic splanchnic area. The effect of portal decompression on splanchnic and systemic ET-1 levels deserves further investigation."],["dc.identifier.doi","10.1034/j.1600-0676.2000.020001060.x"],["dc.identifier.gro","3151647"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8464"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","chake"],["dc.relation.issn","1478-3223"],["dc.title","Systemic and splanchnic endothelin-1 plasma levels in liver cirrhosis before and after transjugular intrahepatic portosystemic shunt (TIPS)"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of the American College of Cardiology"],["dc.bibliographiccitation.volume","43"],["dc.contributor.author","Ferrari, M."],["dc.contributor.author","Hellige, Gerhard"],["dc.contributor.author","Schlosser, M."],["dc.contributor.author","Werner, Gerald"],["dc.contributor.author","Frerichs, Inez"],["dc.contributor.author","Damm, C."],["dc.contributor.author","Guyenot, V."],["dc.contributor.author","Figulla, H. R."],["dc.date.accessioned","2018-11-07T10:50:24Z"],["dc.date.available","2018-11-07T10:50:24Z"],["dc.date.issued","2004"],["dc.identifier.doi","10.1016/S0735-1097(04)91833-5"],["dc.identifier.isi","000189388501836"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48640"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.publisher.place","New york"],["dc.relation.conference","54th Annual Scientific Session of the American-College-of-Cardiology"],["dc.relation.eventlocation","New Orleans, LA"],["dc.relation.eventstart","2004"],["dc.title","Percutaneous aortic valve replacement with a self-expandable stent-valve in the beating heart: In vivo stress testing in an animal model"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","943453"],["dc.bibliographiccitation.journal","Cardiology research and practice"],["dc.bibliographiccitation.lastpage","943453"],["dc.bibliographiccitation.volume","2009"],["dc.contributor.author","Krizanic, F."],["dc.contributor.author","Sigler, M."],["dc.contributor.author","Figulla, H. R."],["dc.date.accessioned","2019-07-09T11:52:42Z"],["dc.date.available","2019-07-09T11:52:42Z"],["dc.date.issued","2009"],["dc.description.abstract","Objectives. The transvascular closure of patent foramen ovale (PFO) with self-expanding devices carries the risk of left atrial thrombus formation related to material protruding into the left atrium. Thus, we developed a novel device with flat left atrial disc geometry. We evaluated feasibility, handling, and biocompatibility in a porcine animal model. Methods. Implantation of an Occlutech Figulla PFO device was performed in 10 mini pigs using fluoroscopy and intra-cardiac ultrasound after transseptal puncture of the interatrial septum. Angiographic follow-up was performed after six and twelve weeks. Results. Implantation was successful in 100%. There were no further implant related complications. One procedure related death occurred, as one animal died of ventricular tachycardia due to mispunture of the interatrial septum. Angiographic studies showed no residual shunt during follow-up. Histopathological evaluation could demonstrate partial neoendothelialization after 6 weeks with completion after 12 weeks. The devices were incorporated into connective tissue containing fibro muscular cells. An only mild inflammatory reaction was detected locally related to the polyester fibers. Conclusion. In terms of feasibility and handling, the new device does not seem to be inferior to other presently used implantation systems. Good biocompatibility was demonstrated with rapid and complete neoendothelialization."],["dc.identifier.doi","10.4061/2009/943453"],["dc.identifier.pmid","19946631"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5825"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60254"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2090-0597"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Transvenous closure of patent foramen ovale: preliminary results with a new self-expanding nitinol wire mesh in a Swine model."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1326"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Heart"],["dc.bibliographiccitation.lastpage","1331"],["dc.bibliographiccitation.volume","90"],["dc.contributor.author","Ferrari, M."],["dc.contributor.author","Figulla, H. R."],["dc.contributor.author","Schlosser, M."],["dc.contributor.author","Tenner, I."],["dc.contributor.author","Frerichs, Inez"],["dc.contributor.author","Damm, C."],["dc.contributor.author","Guyenot, V."],["dc.contributor.author","Werner, Gerald"],["dc.contributor.author","Hellige, Gerhard"],["dc.date.accessioned","2018-11-07T10:44:17Z"],["dc.date.available","2018-11-07T10:44:17Z"],["dc.date.issued","2004"],["dc.description.abstract","Objectives: To evaluate the feasibility of percutaneous aortic valve replacement without cardiac arrest in animal experiments. Methods: A self expanding nitinol stent, containing pulmonary valves from pigs in its proximal part, was implanted in six pigs (94-118 kg) by means of a 25 French catheter through the left subclavian artery under guidance of fluoroscopy and transoesophageal echocardiography. During stent deployment the original aortic valve was pushed against the aortic wall by the self expanding force of the stent while the new valve was expanded. Results: It was possible to replace the aortic valve in the beating heart in four pigs (67%) with no complication or relevant drop in blood pressure. The procedure failed in two pigs (33%) due to dysfunction of the catheter device in one case and to problems with correct positioning in the left ventricular outflow tract in the other. After successful stent valve implantation, dopamine was infused in doses of 5 mug/kg/min, 10 mug/kg/min, and 15 mug/kg/min. Cardiac output increased from 4.4 to 8.8 l/min and the mean arterial pressure rose from 79 to 105 mm Hg. The maximum peak to peak pressure gradient across the valve carrying stent reached a maximum of 8 mm Hg under dopamine infusion. All pigs were killed six hours after transvascular aortic valve replacement. The chest was opened, and the left ventricle and the ascending aorta were carefully inspected. There were no signs of malfunction of the implant, of damage of the aortic vessel wall, or of obstruction of the coronary ostia. Conclusions: Percutaneous aortic valve replacement with a self expanding nitinol stent in the beating heart is possible. The device was safe under pharmacological stress test. After successful chronic animal experiments, this concept may become a feasible option for treating patients with relevant aortic valve disease but where open heart surgery would be risky."],["dc.identifier.doi","10.1136/hrt.2003.028951"],["dc.identifier.isi","000224477000019"],["dc.identifier.pmid","15486135"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47235"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1355-6037"],["dc.title","Transarterial aortic valve replacement with a self expanding stent in pigs"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","818"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal of Hepatology"],["dc.bibliographiccitation.lastpage","824"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Nolte, W."],["dc.contributor.author","Schindler, C. G."],["dc.contributor.author","Figulla, H. R."],["dc.contributor.author","Wuttke, Wolfgang"],["dc.contributor.author","Hufner, M."],["dc.contributor.author","Hartmann, Hans"],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2018-11-07T09:00:58Z"],["dc.date.available","2018-11-07T09:00:58Z"],["dc.date.issued","2001"],["dc.description.abstract","Background/Aims: Liver cirrhosis is frequently associated with sexual dysfunction and hormonal abnormalities, To evaluate the effect of portosystemic shunting on sex steroid serum concentrations, a prospective study was performed in cirrhotic patients treated consecutively and electively by transjugular intrahepatic portosystemic stent shunt (TIPS). Methods: In 27 patients with liver cirrhosis we measured serum levels of testosterone (T), sexual hormone binding globulin (SHBG), luteinizing hormone, follicle-stimulating hormone, dehydroepiandrosterone sulfate, androstenedione (A), estradiol (E-2), 17-OH-progesterone and the T/SHBG ratio before and 3 months after TIPS, Results: In men (n = 17) 3 months after TIPS, A and E-2 significantly increased, with mean serum levels rising from 4.4 +/- 2.5 to 5.6 +/- 2.9 ng/ml (P = 0.04) and from 27 +/- 9 to 40 +/- 19 pg/ml (P = 0.003), respectively. In contrast to A the increase of E-2 persisted at 9 and 15 months after TIPS, Erectile dysfunction increased from 30% before TIPS to 70% after TIPS, In women (n = 10) A and E-2 levels did not change significantly after TIPS. Conclusions: TIPS aggravated hormonal dysbalance of ses steroids in favor of estrogens (hyperestrogenism) in men, (C) 2001 European Association for the Study of the Liver. Published by Elsevier Science B.V. All rights reserved."],["dc.identifier.doi","10.1016/S0168-8278(01)00052-6"],["dc.identifier.isi","000169542500005"],["dc.identifier.pmid","11451164"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24297"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1600-0641"],["dc.relation.issn","0168-8278"],["dc.title","Increase of serum estradiol in cirrhotic men treated by transjugular intrahepatic portosystemic stent shunt"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]